Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

This research study hopes to examine the effects of Coenzyme Q10 on doxorubicin (Adriamycin) metabolism during breast cancer treatment. Doxorubicin is a lifesaving breast cancer treatment.

However, approximately 3-20% of women who receive doxorubicin treatment experience some damage to their heart muscle. Coenzyme Q10 is a fat soluble antioxidant dietary supplement that may protect against this heart damage during doxorubicin treatment. It is unknown how Coenzyme Q10 may interact with doxorubicin. This study will assess the effects of Coenzyme Q10 on doxorubicin metabolism.

Further Study Information

This is a phase I randomized, placebo-controlled, cross-over pharmacokinetic and dose-finding study to assess the safety of CoQ10 during doxorubicin treatment for breast cancer in a maximum of 18 patients. Safety will be assessed by measuring 1) intra-patient differences in doxorubicin and its active metabolites, with and without CoQ10, and 2) adverse events. We hypothesize that CoQ10 administration during doxorubicin treatment is safe and will not affect doxorubicin active metabolites. Using three dose levels of CoQ10, the maximum tolerated dose (MTD) will be determined by assessing change in doxorubicin concentration (area under the curve (AUC), change in peak concentration levels (Cmax)), and adverse events.

Eligibility Criteria

Inclusion Criteria:

• Diagnosis of early stage breast cancer (stage I, II, or III);

• Scheduled to receive at least four rounds of dose dense doxorubicin therapy in the neoadjuvant or adjuvant setting;

• No other history of prior chemotherapy, radiation, or hormonal therapy in the previous 5 years;

• For women receiving adjuvant therapy, single lumen implanted venous access device (i.e. single port) for unilateral cancer and double lumen implanted venous access device (i.e. double port) for bilateral breast cancer

• Age 21 years or older;

• ECOG performance status ≤ 2 (Karnofsky > 60%);

• Normal organ and marrow function defined as: Leukocytes ≥ 3,000/uL, Absolute neutrophils count (ANC) ≥ 1,500/uL at baseline, Platelets ≥ 100,000/uL, Total bilirubin ≤ 1.5 X normal institutional limits, AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional ULN, Serum creatinine within normal institutional limits;

• Left ventricular ejection fraction > 55%;

• No history of CoQ10 supplement use within 30 days of initiating study drug;

• No uncontrolled or significant co-morbid illness;

• Not pregnant, not breastfeeding, and not planning on becoming pregnant during the course of the study;

• Willingness to comply with all study intervention and follow-up procedures;

• Ability to speak English or Spanish; and

• Ability to provide informed consent.

Exclusion Criteria:

• Inability to understand or an unwillingness to sign a written informed consent document;

• Any significant toxic side effects related to first or second dose of doxorubicin/cyclophosphamide chemotherapy or biologic therapy that did not resolve to less than a CTCAE 3.0 grade 3 non-hematological toxicity;

• Currently using any investigational agent;

• Unstable or severe intercurrent medical condition that, in the opinion of the investigator, might interfere with the participant's ability to follow the protocol or achieve study objectives;

• Psychological or sociological conditions, addictive disorders, or family problems that would preclude adherence with study drug or compliance with the protocol

• Women who report pregnancy, are breast feeding, or have a positive pregnancy test;

• Use of CoQ10 supplement use within 30 days of initiating study drug;

• Use of over-the-counter nutritional vitamin greater than 5x RDA;

• Fish allergy (due to fish-based softgel shell);

• Currently taking FDA cardioprotective drugs, such as Zinecard (dexrazoxane);

• History of chronic hepatitis B, hepatitis C, and HIV infection;

• Problems swallowing oral medications due to prolonged emesis, mucositis, esophageal dysfunction, etc.; and,

• Currently taking any form of antioxidant supplements while on study.

• Use of warfarin.

• Kosher (due to fish-based softgel shell)

• Dietary restriction of tilipia (due to tilipia fish-based softgel shell)

• Titanium Dioxide allergy (due to the opaque coloring used in the softgel).

Trial Contact Information

Trial Lead Organizations/Sponsors

Heather Greenlee, PhD, ND

Heather Greenlee

Principal Investigator

Herbert Irving Comprehensive Cancer Center Clinical Research Management Office

Ph: 212-305-8615

U.S.A.
New York
	New York
	Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
		Heather Greenlee	Principal Investigator
		Dawn Hershman	Sub-Investigator
		Katherine Crew, MD, MS	Sub-Investigator
		Matthew Maurer, MD	Sub-Investigator
		Serge Cremers, PharmD, PhD	Sub-Investigator
		Kevin Kalinsky	Sub-Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00976131
Information obtained from ClinicalTrials.gov on February 21, 2013

Back to Top